![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
PMC:7242007 / 7970-8342
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
357 | 170-178 | Species | denotes | patients | Tax:9606 |
358 | 315-325 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
361 | 80-83 | Species | denotes | HIV | Tax:12721 |
362 | 88-91 | Species | denotes | HCV | Tax:11103 |
370 | 45-53 | Disease | denotes | COVID‐19 | MESH:C000657245 |
371 | 63-74 | Disease | denotes | co‐infected | MESH:D060085 |
372 | 129-169 | Disease | denotes | HIV mono‐infected or HIV/HCV co‐infected | MESH:D015658 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T33 | 80-83 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T34 | 129-132 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T35 | 150-153 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T36 | 294-302 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T108 | 45-53 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T109 | 315-319 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T25 | 254-258 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T26 | 259-263 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T81 | 0-372 | Sentence | denotes | 12 There have been only sporadic reports of COVID‐19 in those co‐infected with HIV and HCV, and unique considerations in either HIV mono‐infected or HIV/HCV co‐infected patients would be of adjustments to antiretroviral therapy (ART) based on potential drug‐drug interactions (DDIs); further, antibody response to SARS‐CoV‐2 may be impaired or delayed in this population. |